Premium
New choices, new challenges: Anti‐TNF versus anti‐integrin molecule therapy in IBD
Author(s) -
Langenberg Daniel R
Publication year - 2016
Publication title -
journal of gastroenterology and hepatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.214
H-Index - 130
eISSN - 1440-1746
pISSN - 0815-9319
DOI - 10.1111/jgh.13347
Subject(s) - vedolizumab , medicine , infliximab , adalimumab , adverse effect , tumor necrosis factor alpha , inflammatory bowel disease , golimumab , immunology , thalidomide , clinical trial , clinical endpoint , disease , oncology , intensive care medicine , multiple myeloma